<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067350</url>
  </required_header>
  <id_info>
    <org_study_id>38RC15.168</org_study_id>
    <nct_id>NCT03067350</nct_id>
  </id_info>
  <brief_title>Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients</brief_title>
  <acronym>VORIGENE</acronym>
  <official_title>Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: A pharmacogenetic score integrating both CYP3A genotypes could be influence
      initial trough voriconazole plasma concentrations and thus useful to adapt a priori
      voriconazole dosing in order to get adequate voriconazole exposure as possible after starting
      treatment.

      Main Objective: To determine predictive value of a combined pharmacogenetic score on onset of
      trough voriconazole plasma concentration inferior than lower therapeutic target.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Voriconazole (VRC), the gold-standard treatment of invasive aspergillosis is characterized by
      variables and nonlinear pharmacokinetics, causing many under- or over-dosing. A link exist
      between trough plasma concentrations (Cmin) of VRC and effectiveness but also its toxicity.
      Thus the longitudinal therapeutic drug monitoring of VRC is now recommended with a
      therapeutic range between 1 and 5 mg/L. The pharmacokinetic variability of VRC is in part
      explained by its metabolism, mainly dependent on cytochrome P 450 (CYP), particularly
      CYP2C19, 3A4, 3A5; all these CYP exhibiting genetic polymorphisms. The authors, recently
      shown, and for the first time , in a retrospective study conducted in 29 patients allogeneic
      hematopoietic stem cell that initial VRC Cmin adjusted the dose was not only influenced by
      the route of administration but also by a pharmacogenetics score whose determination is to
      assign each genotype CYP2C19 and CYP3A a score expressed in a arbitrary units.

      The combined pharmacogenetic score was strongly correlated with the original Cmin (r= -0.748;
      p = 0.002) and was the only independent predictor of initial Cmin (after adjusting the dose
      and the route of administration). In addition, none of the patients having a genetic score &lt;2
      (ie metabolizing capacity of reduced VRC) did not show an initial Cmin below 1 mg/L, while
      the initial Cmin was below this threshold efficiency in 47% of patients with a genetic score
      &gt;2. The aim of this new study is to confirm the impact of the pharmacogenetic score on the
      initial VRC Cmin over a larger prospective cohort of 60 adult patients with
      onco-hematological diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>number of initial voriconazole trough plasma concentration in the therapeutic range (1-4mg/l)</measure>
    <time_frame>concentration measured between 5 to 10 days after voriconazole treatment initiation</time_frame>
    <description>Initial voriconazole trough plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>initial voriconazole trough plasma concentrations adjusted on the dose</measure>
    <time_frame>concentration measured between 5 to 10 days after voriconazole treatment initiation</time_frame>
    <description>Initial voriconazole trough plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with therapeutic success</measure>
    <time_frame>3 months after voriconazole therapy initiation</time_frame>
    <description>treatment outcome determined 3 months after voriconazole initiation (failure, stable response, success)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with adverse effects</measure>
    <time_frame>duration of voriconazole treatment (maximum length of follow-up : 3 months)</time_frame>
    <description>adverse effects include neurological disorders such as visual disturbance and/or hallucinations and hepatotoxicity (evaluated by ALAT/ASAT, bilirubin and γ-GT levels),</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Invasive Aspergillosis</condition>
  <condition>Haematological Cancer Patients</condition>
  <condition>Voriconazole</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from haematological cancer Followed at the hematolofic clinic of
        Grenoble University Hospital Starting treatment by voriconazole whatever the route of
        administration
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients suffering from haematological cancer

        Exclusion Criteria:

          -  less than 18-years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elodie GAUTIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elodie GAUTIER, PH</last_name>
    <phone>0033476765492</phone>
    <email>EGautier@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital, Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gautier-Veyret E, Fonrose X, Tonini J, Thiebaut-Bertrand A, Bartoli M, Quesada JL, Bulabois CE, Cahn JY, Stanke-Labesque F. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. Antimicrob Agents Chemother. 2015 Apr;59(4):2305-14. doi: 10.1128/AAC.04838-14. Epub 2015 Feb 2.</citation>
    <PMID>25645831</PMID>
  </reference>
  <reference>
    <citation>Gautier-Veyret E, Fonrose X, Stanke-Labesque F. A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure? Int J Antimicrob Agents. 2016 Aug;48(2):221-2. doi: 10.1016/j.ijantimicag.2016.05.002. Epub 2016 Jun 7.</citation>
    <PMID>27318623</PMID>
  </reference>
  <reference>
    <citation>Tonini J, Bailly S, Gautier-Veyret E, Wambergue C, Pelloux H, Thiébaut-Bertrand A, Cornet M, Stanke-Labesque F, Maubon D. Contribution of a Simple Bioassay in Effective Therapeutic Drug Monitoring of Posaconazole and Voriconazole. Ther Drug Monit. 2015 Oct;37(5):685-8. doi: 10.1097/FTD.0000000000000199.</citation>
    <PMID>26384041</PMID>
  </reference>
  <reference>
    <citation>Tonini J, Thiébaut A, Jourdil JF, Berruyer AS, Bulabois CE, Cahn JY, Stanke-Labesque F. Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother. 2012 Oct;56(10):5247-52. doi: 10.1128/AAC.00815-12. Epub 2012 Jul 30.</citation>
    <PMID>22850515</PMID>
  </reference>
  <reference>
    <citation>Jourdil JF, Tonini J, Stanke-Labesque F. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 1;919-920:1-9. doi: 10.1016/j.jchromb.2012.12.028. Epub 2013 Jan 9.</citation>
    <PMID>23384531</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>voriconazole</keyword>
  <keyword>pharmacogenetics</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

